Market Cap 50.68M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio 4.24
Volume 6,753,300
Avg Vol 1,729,976
Day's Range N/A - N/A
Shares Out 257.23M
Stochastic %K 86%
Beta 2.52
Analysts Sell
Price Target $1.77

Latest News on ADAP

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 13 days ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update


Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 5 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates


Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 8 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates


Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 11 months ago

Adaptimmune Reports Q1 2024 Financial and Business Updates


Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech


Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program


Adaptimmune: Spinning Sarcoma Into Gold

Sep 12, 2023, 8:48 AM EDT - 1 year ago

Adaptimmune: Spinning Sarcoma Into Gold